Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study-Reference-Cited by-同舟云学术

Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study

Published:2016-02-10 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Stein Alexander,Quidde Julia,Schröder Jan Klaus,Göhler Thomas,Tschechne Barbara,Valdix Annette-Rosel,Höffkes Heinz-Gert,Schirrmacher-Memmel Silke,Wohlfarth Tim,Hinke Axel,Engelen Andreas,Arnold Dirk

Funder

F. Hoffman-La Roche

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2113-8

Reference43 articles.

1. Schmoll HJ, Stein A. Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection. Nat Rev Clin Oncol. 2014;11(2):79–80.

2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, on behalf of the EGWG. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2014;25 Suppl 3:iii1–9.

3. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282–92.